Multiagonists of the “incretin axis” as a promising tool for managing cardiometabolic risk in visceral obesity
Currently, the world experiences an increase in obesity prevalence, resulting in an increase in the incidence of diseases in which it is one of the leading factors, primarily type 2 diabetes and cardiovascular disease. This limits the effectiveness of preventive measures and determines the need to i...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-05-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4755 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Currently, the world experiences an increase in obesity prevalence, resulting in an increase in the incidence of diseases in which it is one of the leading factors, primarily type 2 diabetes and cardiovascular disease. This limits the effectiveness of preventive measures and determines the need to introduce more effective approaches. Evidence of the key role of intestinal peptide hormones (incretins) in the normalization of body weight and metabolic processes after bariatric interventions became the basis for studying pharmacological methods for treating obesity and related complications aimed at the “incretin axis”. In order to achieve greater efficacy compared to monotherapy with glucagon-like peptide-1 (GLP-1) agonists, studies are performed on unimolecular multiagonists developing on the basis of GLP-1 agonists and effecting on various components of the “incretin axis” by competitive activation of numerous receptors, in first of all, receptors for glucose-dependent insulinotropic polypeptide and glucagon. This review analyzes the results of clinical trials and discusses the prospects for introduction of “incretin axis” multi-agonists for patients with visceral obesity syndrome. |
|---|---|
| ISSN: | 1560-4071 2618-7620 |